Toolgen said Monday that it has agreed to cooperate with Rebelbio, a seed biotech accelerator of global venture capital SOSV, to provide Toolgen’s gene correction platform to start-up companies that want to use such technology.
|Officials from Toolgen and Rebelbio pose after signing the MOU agreement|
"We are pleased to announce our collaboration with Rebelbio, who has an impressive portfolio of biotechnology initiatives," said Kim Jong-moon, CEO of Toolgen Toolgen, Rebelbio agree to help bio ventures. "Working with innovative start-up companies will enable us to expand the scope of our gene correction technology further and increase our enterprise value."
Rebelbio also showed enthusiasm toward the agreement.
"Our company will do our utmost to make start-up companies actively commercialize gene correction technology," said Bill Liao, founder of Rebelbio "We plan to develop stronger partnerships with Toolgen in the future."
The memorandum of understanding signed by the two companies is likely to spread Toolgen’s gene correction technology through SOSV's global network to some fields such as agriculture and healthcare. Toolgen has signed another MOU with plant biotechnology company PlantEdit. The two companies agreed to cooperate to develop environmentally-friendly and consumer-driven sustainable crops
Toolgen’s CRISPR genetic scissor is a key tool in gene correction technology. It is widely used in life sciences because it can selectively correct specific genetic information in cells.
Monsanto, the world's largest seed company, and Thermo Fisher Scientific, a global company in the field of products and services for life sciences research, have licensed Toolgen’s technology.
<© Korea Biomedical Review, All rights reserved.>